Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

4.885 -0.195 (-3.84%)
Streaming Delayed Price Updated: 2:51 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Xeris Biopharma Updates Its Outlook for 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why Xeris Biopharma Shares Are Trading Higher Today
Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares are trading higher by around 9% after the 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Xeris Pharmaceuticals's Earnings Outlook
Via Benzinga
Xeris Biopharma Reports Third Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Xeris Biopharma Reports Second Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Ships One Millionth Gvoke® Unit
From Xeris Biopharma Holdings, Inc.
Via Business Wire
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports First Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
From Xeris Biopharma Holdings
Via Business Wire
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS